TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06319391

Intervention type: OTHER
Intervention: CYP3A5*1*、CYP3A5*1*3
Description: 2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system. After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.

Intervention type: OTHER
Intervention: CYP3A5*3*3
Description: 2ml of venous blood was drawn and placed in an EDTA anticoagulant tube. Peripheral blood genomic DNA was extracted according to the instructions of the DNA extraction kit.The reaction system was prepared by polymerase chain reaction (PCR) according to the instructions of PCR amplification system.After 25g/L agarose gel electrophoresis, the bands of amplified products were observed under UV lamp. The PCR products were purified by enzymolysis. The purified product was prepared according to sequencing PCR amplification system. After 1min predenaturation at 96℃, denaturation at 96℃ for 30s, annealing at 56 ℃ for 30s and extension at 72℃ for 1 cycle. A total of 25 cycles were performed for sequencing PCR amplification. The amplified products were purified by ethanol precipitation method.
Study: NCT05450666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobility exercises
Description: Before starting the exercise program, a video and exercise program including the importance of shoulder mobilization and stabilization and the knowledge of how to contract the right muscle groups will be shared in order to raise awareness of the athletes. Following the evaluations, in addition to the classical training programs, the athletes will perform the Wall Angels and Anterior Shoulder Stretch, Shoulder Circle Rotation, Prone Shoulder Controlled Articular Rotations and Shoulder Side Stretch exercises, Prone I, T, W, Y's 3 days a week for 8 weeks, accompanied by the same physiotherapist.
Study: NCT04941755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study: NCT06006520

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No exercises will be given.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oro-granary exercises.
Description: soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oro-granary exercises.
Description: soft palate exercises language exercises facial exercises stomatognathic functions swallowing and chewing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercises
Description: We can think of aerobic exercise as a low-intensity long-term activity using large muscle groups (between 60-80% of maximal heart rate). For example; It includes activities such as walking, cycling, jogging, aerobic dancing, swimming.
Study: NCT06357533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Datopotamab Deruxtecan IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Rilvegostomig IV (intravenous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab IV (intravenous)
Study: NCT06139081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen delivery mode
Description: After the implantation of the mirror, nasal catheter was used to give oxygen through the mouth
Study: NCT05924919

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole-body Passive Heat Therapy (HT)
Description: The whole-body passive heat therapy (HT) intervention will consist of an acute bout of infrared sauna for 25 minutes at 60°C. Participants will lie supine on a memory foam pad.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermoneutral Control (CON)
Description: Participants will remain in a room temperature environment (22°C) underneath the infrared domes for 25 minutes.
Study: NCT04625647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study: NCT06472219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 30 mg
Description: This is a glucocorticoid like cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic and vasoconstrictive effects. It binds to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. It has a short duration of action as the half-life is 2.1-3.5 hours and 98% is eliminated in urine. On 21 June 1955 it was granted FDA approval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This a tablet identical to prednisolone.
Study: NCT06025877

Intervention type: OTHER
Intervention: PrecivityAD2(TM) blood test
Description: The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.

Intervention type: OTHER
Intervention: PrecivityAD2(TM) blood test
Description: The PrecivityAD2 blood test measures plasma amyloid beta (Aβ) peptides 42 and 40 (Aβ42/40) Ratio and phosphorylated tau (p-tau) compared to non-phosphorylated tau (np-tau) at amino acid 217 of the tau peptide (p-tau217/np-tau217) ratio to determine whether a patient with signs or symptoms of cognitive impairment is likely to have brain amyloid plaques, a pathological hallmark of AD.
Study: NCT05345184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Suicide Prevention for psychosis (CBSPp)
Description: Cognitive and behavioral approach to suicide prevention tailored for individuals with psychosis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as Usual (SAU)
Description: Standard psychiatric and behavioral services provided at community mental health (e.g., case management, medication management)
Study: NCT06516588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Dirrect Current Stimulation
Description: tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Dirrect Current Stimulation
Description: tDCS will deliver direct current through rubber electrodes in saline-soaked sponges. Device sends a low-level current from the positive electrode, the anode, to the negative electrode, the cathode. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35cm2) and delivered by a specially developed, battery-driven, constant current stimulator with a maximum output of 10mA. The anode will be placed over the LDLPFC and the cathode over the contralateral supra-orbital area.
Study: NCT06634758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing interventions based on the Watson Human Caring Model
Description: In the literature review, it was noticed that nursing care based on the Watson Human Caring Model was applied to various patient groups but not to patients with MS.
Study: NCT05570526

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Puritan's Pride ® Melatonin 5mg tablets orally once daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study: NCT05197010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home based exercise program via a smartphone application
Description: Daily home based exercise program (30min/day, 7days/week for 6 weeks).
Study: NCT04596449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study intervention
Description: The sleep structure of healthy volunteers will be recorded (9 Electroencephalograms (EEG), 2 Electrooculograms (EOG), 2 Electromyograms (EMG) and 2 Electrocardiograms (ECG)) during 1 night. The characteristics of the spindle (density, frequency and amplitude) will be automatically analyzed from purified EEG during Non Rapid Eye Movement sleep (NREM).~Volunteers will completed a neuropsychological evaluation that will evaluate Sustained attention (simple reaction time test), Vigilance (TAP Vigilance), Sustained and selective attention (CPT II), Inhibition (Stroop test), Mental flexibility (TAP flexibility) , Executive operation (Tower of London), Short-term memory (Wechsler code test).~Driving performance will be analyzed as part of a complex scenario involving attentional and high-level functions on a driving simulator.
Study: NCT05178589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Unit TENS
Description: TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Single unit TENS was administered via 2 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two Unit TENS
Description: TENS was administered by the participant at home. Application was limited to the abdominal area and instructed to be placed at the location of pain. Double unit TENS was administered via 4 channels. Participants chose an intensity of comfort and continued the treatment for 30-90 minutes per session with unlimited sessions allowed per day.
Study: NCT05621200

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial stimulation over the cerebellar hemispheres
Description: Single session of Transcranial stimulation over the cerebellar hemispheres

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation over the cerebellar hemispheres
Description: Single session of Transcranial stimulation over the cerebellar hemispheres

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial stimulation over the cerebellar hemispheres
Description: Single session of Transcranial stimulation over the cerebellar hemispheres
Study: NCT05388188

Intervention type: DRUG
Intervention: sublingual sufentanil
Description: Dsuvia in patients with SCD VOC as a bridging medication.
Study: NCT04923529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.~Days 6 through 7: Recovery~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Recovery
Study: NCT06232356

Intervention type: DIAGNOSTIC_TEST
Intervention: Mobile Web App
Description: all participants will undergo an assessment of respiratory health by analyzing the sound of exhaled air recorded by the participant's mobile phone
Study: NCT06392737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-AI guided cognitive prostate targeted biopsy
Description: Before prostate biopsy, the MR images of patients in the AI-cTB group were uploaded to the AI software. Then the images with suspicious lesions highlighted by AI software were viewed by urologists. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine cognitive prostate targeted biopsy
Description: Before prostate biopsy, the MR images and reports were viewed by urologists preceding the biopsy. Biopsies were performed under the guidance of TRUS through the transrectal or transperineal route.
Study: NCT04860635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F14 (sustained release celecoxib)
Description: Celecoxib in BEPO® drug delivery system
Study: NCT04523142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyclASol Ophthalmic Solution
Description: Cyclosporine A solution in vehicle
Study: NCT06147219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interlocking intramedullary tibial nail
Description: primary dynamization versus standard interlocking intramedullary tibial nail

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interlocking intramedullary tibial nail
Description: primary dynamization versus standard interlocking intramedullary tibial nail
Study: NCT06049667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTQ2494 tablet
Description: Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria.~For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle).~Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
Study: NCT04911920

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Patient Rated Tennis Elbow Evaluation
Description: Participants are asked to complete questionnaires at three measurement time points.
Study: NCT06775860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-332 Tablets
Description: ICP-332 will be administered as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ICP-332 Placebo Tablets
Description: ICP-332 Placebo will be administered as tablet
Study: NCT06775626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanon NXT® subdermal implant
Description: Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel 68mg implant
Description: Each implant contains 68 mg of etonogestrel. The release rate is approximately 60-70 mcg/day in the 5th-6th week and reduces to approximately 35-45 mcg/day at the end of the first year; 30-40 mcg/day at the end of the second year and 25-30 mcg/day at the end of the third year.~It will be evaluation before, 3, 6, 9 and 12 months after implant insertion.Participants' use of the device will be evaluated for one year
Study: NCT06776029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: FMT is delivered via oral capsules. Fecal microbiota capsules are given by 8 sessions over a 12-week period, with the initial 3 sessions every other day in the first week and the subsequent sessions every two weeks. The FMT regimen involves oral intake of 40 capsules per session. The best supportive care is performed when necessary, including oral medicine, enema, blood transfusion, and endoscopic procedures.
Study: NCT04737668

Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill with Virtual Reality
Description: VR game

Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill with distraction
Description: Video

Intervention type: OTHER
Group type: OTHER
Intervention: Intrathecal pump refill
Description: daily routine care for pump refill
Study: NCT05750225

Intervention type: OTHER
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

Intervention type: OTHER
Intervention: Standard of care
Description: 12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

Intervention type: OTHER
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.

Intervention type: OTHER
Intervention: Patient satisfaction questionnare
Description: VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.
Study: NCT06466044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ear point pressure bean method in ear concha area
Description: The method of pressing beans on auricular points is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, relevant auricular points are selected, and appropriate stimulation such as kneading, pressing, pinching and pressing is given to the seeds of Vaccaria seed attached to the concha auricularis, so that the auricular points can produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Ear point pressure bean method in earlobe
Description: The auricular point pressing bean method is based on the meridian theory and viscera theory in the basic theory of traditional Chinese medicine, combined with the knowledge of modern medical anatomy, and from the perspective of syndrome differentiation and treatment, the relevant auricular points are selected, and the seeds attached to the ear lobe, which is the least innervated part of vagus nerve, are given appropriate stimulation such as kneading, pressing, pinching and pressing, so that the auricular points produce acid, numbness, swelling and pain slowly and continuously. For therapeutic purposes.
Study: NCT04744896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis(3 max cool shaping)
Description: cryolioplysis applied over abdomen area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryolipolysis(3 max cool shaping)
Description: cryolioplysis applied over abdomen area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill (jkexer focus 8020A)
Description: aerobic training ( high intensity interval training)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill (jkexer focus 8020A)
Description: aerobic training ( high intensity interval training)
Study: NCT05045794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaSmart Liver Machine Perfusion System
Description: Following donor liver retrieval, preservation using static cold storage, and back table preparation in the transplant center operating room, the organ will be flushed with Belzer UW Machine Perfusion Solution (MPS) and perfused through the cannulated portal vein using cold, actively oxygenated MPS that is circulated at low pressure for 90 minutes to 5 hours. After disconnection from the device, donor liver implantation and reperfusion will proceed in accordance with institutional care standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static cold storage
Description: Donor liver retrieval and preservation using standard of care cold storage methods

Intervention type: OTHER
Group type: OTHER
Intervention: Static cold storage
Description: Donor liver retrieval and preservation using standard of care cold storage methods
Study: NCT04339088

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to assess quality of life
Study: NCT06205199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone was injected into the subarachnoid space
Description: The dose of hydromorphone is 50 micrograms
Study: NCT04401319

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation for Crossover Study
Description: Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC Stimulation for Crossover Study
Description: Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AG Stimulation for Crossover Study
Description: Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. A single session will be conducted.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation for Parallel Study
Description: Stimulation will be delivered on the dorsolateral prefrontal cortex (DLPFC) or the angular cortex (AG) using a sham coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC Stimulation for Parallel Study
Description: Stimulation will be delivered on the left dorsolateral prefrontal cortex (DLPFC) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AG Stimulation for Parallel Study
Description: Stimulation will be delivered on the left angular cortex (AG) using a real coil for 20 minutes with a frequency of 20Hz (train duration: 4s; inter-train interval: 26s; 3200 pulses at 80% of the resting motor threshold ) in one session. Twenty sessions will be conducted.